Denali Therapeutics Secures $200M Royalty Funding Following U.S. FDA Accelerated Approval Of Tividenofusp Alfa

Denali Therapeutics has secured $200 million in gross proceeds through a Royalty Agreement following the accelerated approval of its drug tividenofusp alfa by the U.S. FDA on March 24, 2026. The funding was finalized on March 27, 2026, marking a significant financial milestone for the company.